Animal models of brain dysfunction in phenylketonuria

Molecular Genetics and Metabolism

Volumn 99, Issue SUPPL., 2010, Pages

  Martynyuk, A E ^a   van Spronsen, F J ^b   Van der Zee, E A ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

BTBR Pahenu2 mouse; Dopamine; Experimental phenylketonuria; Glutamate; Neurotransmitters; Phenylketonuria; PKU; Serotonin

Indexed keywords

AMINO ACID DERIVATIVE; GLUTAMIC ACID; LARGE NEUTRAL AMINO ACID; NEUROTRANSMITTER; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; SEROTONIN; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ANIMAL BEHAVIOR; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; ENZYME DEFICIENCY; HUMAN; MEMBRANE TRANSPORT; NEUROANATOMY; NONHUMAN; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ANIMALIA;

EID: 72249105525     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.10.181     Document Type: Article

References (62)

1. Scriver C.R., Levy H., and Donlon J J. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Valle D., Beaudet A.L., Vogelstein B., Kinzler K.W., Antonarakis S.E., Ballabio A., Scriver C.R., Sly W.S., Childs B., Bunz F., Gibson K.M., and Mitchell G G. (Eds). The Online Metabolic & Molecular Bases of Inherited Disease (2008), Springer, Berlin, Heidelberg Chapter 77
2. van Spronsen F.J., Hoeksma M., and Reijngoud D.J. Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?. J. Inherit. Metab. Dis. 32 (2009) 46-51
3. McKean C.M., Boggs D.E., and Peterson N.A. The influence of high phenylalanine and tyrosine on the concentrations of essential amino acids in brain. J. Neurochem. 15 (1968) 235-241
4. Walter J., Lee P.J., and Burgard P. Hyperphenylalaninaemia. In: Fernandes J., Saudubray J.M., van den Berghe G., and Walter J. (Eds). Inborn Metabolic Diseases, Fourth, Revised Edition (2006), Springer, Berlin, Heidelberg 223-232
5. Vorhees C.H., Butcher R.E., and Berry H.K. Progress in experimental phenylketonuria: a critical review. Neurosci. Biobehav. Rev. 5 (1981) 177-190
6. Surtees R., and Blau N. The neurochemistry of phenylketonuria. Eur. J. Pediatr. 159 (2000) S109-S113
7. Binek-Singer P., and Johnson T.C. The effects of chronic hyperphenylalanineminaemia on mouse brain synthesis can be prevented by other amino acids. Biochem. 206 (1982) 407-414
8. Karrer R., and Cahilly G. Experimental attempts to produce phenylketonuria in animals: a critical review. Psychol. Bull. 64 (1965) 52-54
9. Dienel G.A. Chronic hyperphenylalaninemia produces cerebral hyperglycinemia in immature rats. J. Neurochem. 36 (1981) 34-43
10. Smith I., Beasley M.G., and Ades A.E. Intelligence and quality of dietary treatment in phenylketonuria. Arch. Dis. Child. 65 (1990) 472-478
11. Gassió R., Fusté E., López-Sala A., Artuch R., Vilaseca M.A., and Campistol J. School performance in early and continuously treated phenylketonuria. Pediatr. Neurol. 33 (2005) 267-271
12. Huijbregts S.C.J., de Sonneville L.M.J., Licht R., van Spronsen F.J., Verkerk P.H., and Sergeant J.A. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia. 40 (2002) 7-15
13. Huijbregts S., de Sonneville L., Licht R., Sergeant J., and van Spronsen F.J. Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria. Dev. Neuropsychol. 22 (2002) 481-499
14. Huijbregts S.C.J., de Sonneville L.M.J., van Spronsen F.J., Berends I.E., Licht R., Verkerk P.H., and Sergeant J.A. Executive motor control under lower and higher controlled processing demands in early- and continuously-treated phenylketonuria. Neuropsychology 17 (2003) 360-379
15. Hommes F.A. Aminoacidaemias and brain maturation: interference with sulphate activation and myelin metabolism. J. Inherit. Metab. Dis. 8 (1985) 21-22
16. Hommes F.A., and Matsuo K. On a possible mechanism of abnormal brain development in experimental hyperphenylalaninemia. Neurochem. Int. 11 (1877) 1-10
17. Hommes F.A. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. Biochem. Metab. Biol. 46 (1991) 277-287
18. Johnson R., and Shah S.N. Effects of α-methylphenylanine plus phenylalanine treatment during development on myelin in rat brain. Neurochem. Res. 5 (1980) 709-718
19. Hommes F.A., and Moss L. Myelin turnover in hyperphenylalaninaemia. A re-evaluation with the HPH-5 mouse. J. Inherit. Metab. Dis. 15 (1992) 243-251
20. Hughes J.V., and Jonhson T.C. The effects of hyperphenylalaninaemia on the concentrations of aminoacyl-transfer ribonucleic acid in vivo. A mechanism for the inhibition of neural protein synthesis by phenylalanine. Biochem. J. 162 (1977) 527-537
21. Berger R., Springer J., and Hommes F.A. Brain protein and myelin metabolism in hyperphenylalaninemic rats. Cell Mol. Biol. Incl. Cyto. Enzymol. 26 (1980) 31-36
22. Roberts S. Experimental aminoacidemias. In: Lajtha A. (Ed). Handbook of Neurochemistry: Alterations of Metabolites in the Nervous System vol. 10 (1985), Plenum Press, New York 203-218
23. Andersen A.E., and Avins L. Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria. Arch. Neurol. 33 (1976) 684-686
24. McKean C.M. The effects of high phenylalanine concentrations on serotonin and catecholamine metabolism in the human brain. Brain Res. 47 (1972) 469-476
25. Butler I.J., Flynn M.E.O., Seifert Jr. W.E., and Howell R.R. Neurotransmitter defects and treatment of disorders of hyperphenylalaninemia. J. Pediatr. 98 (1981) 729-733
26. H. Lou, Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria, 2 (1985) 150-151.
27. Shedlovsky A., McDonald J.D., Symula D., and Dove W.F. Mouse models of human phenylketonuria, Genetics 134 (1993) 1205-1210
28. McDonald J.D., and Charlton C.K. Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics 39 (1997) 402-405
29. Sarkissian C.N., Scriver C.R., and Mamer O.A. Measurement of phenyllactate, phenylacetate, and phenylpyruvate by negative ion chemical ionization-gas chromatography/mass spectrometry in brain of mouse genetic models of phenylketonuria and non-phenylketonuria hyperphenylalaninemia. Anal. Biochem. 280 (2000) 242-249
30. Smith C.B., and Kang J. Cerebral protein synthesis in a genetic mouse model of phenylketonuria. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 11014-11019
31. Joseph B., and Dyer C.A. Relationship between myelin production and dopamine synthesis in the PKU mouse brain. J. Neurochem. 86 (2003) 615-626
32. Glushakov A.V., Glushakova O., Varshney M., Bajpai L.K., Sumners C., Laipis P.J., Embury J.E., Baker S.P., Otero D.H., Dennis D.M., Seubert C.N., and Martynyuk A.E. Long-term changes in glutamatergic synaptic transmission in phenylketonuria. Brain 128 (2005) 300-307
33. Martynyuk A.E., Ucar D.A., Yang D.D., Norman W.M., Carney P.R., Dennis D.M., and Laipis P.J. Epilepsy in phenylketonuria: a complex dependence on serum phenylalanine levels. Epilepsia. 48 (2007) 1143-1150
34. Shulkin B.L., Betz A.L., Koeppe R.A., and Agranoff B.W. Inhibition of neutral amino acid transport across the human blood-brain barrier by phenylalanine. J. Neurochem. 64 (1995) 1252-1257
35. Sanchez del Pino M.M., Hawkins R.A., and Peterson D.R. Neutral amino acid transport by the blood-brain barrier. Membrane vesicle studies. J. Biol. Chem. 267 (1992) 25951-25957
36. Brenton D.P., and Gardiner R.M. Transport of l-phenylalanine and related amino acids at the ovine blood-brain barrier. J. Physiol. 402 (1988) 497-514
37. Pietz J., Kreis R., Rupp A., Mayatepek E., Rating D., Boesch C., and Bremer H.J. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J. Clin. Invest. 103 (1999) 1169-1178
38. Puglisi-Allegra S., Cabib S., Pascucci T., Ventura R., Cali F., and Romano V. Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. Neuroreport. 11 (2000) 1361-1364
39. Pascucci T., Ventura R., Puglisi-Allegra S., and Cabib S. Deficits in brain serotonin synthesis in a genetic mouse model of phenylketonuria. Neuroreport. 13 (2002) 2561-2564
40. Pascucci T., Andolina D., Ventura R., Puglisi-Allegra S., and Cabib S. Reduced availability of brain amines during critical phases of postnatal development in a genetic mouse model of cognitive delay. Brain Res. 1217 (2008) 232-238
41. Pascucci T., Andolina D., Mela I.L., Conversi D., Latagliata C., Ventura R., Puglisi-Allegra S., and Cabib S. 5-Hydroxytryptophan rescues serotonin response to stress in prefrontal cortex of hyperphenylalaninaemic mice. Int. J. Neuropsychopharmacol. 12 (2009) 1067-1079
42. Koch R., Moseley K.D., Yano S., Nelson Jr. M., and Moats R.A. Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment. Mol. Genet. Metab. 79 (2003) 110-113
43. Embury J.E., Charron C.E., Martynyuk A., Zori A.G., Liu B., Ali S.F., Rowland N.E., and Laipis P.J. PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice. Brain Res. 1127 (2007) 136-150
44. Mattson M.P. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann. N.Y. Acad. Sci. 1144 (2008) 97-112
45. Glushakov A.V., Dennis D.M., Morey T.E., Sumners C., Cucchiara R.F., Seubert C.N., and Martynyuk A.E. Specific inhibition of N-methyl-d-aspartate receptor function in rat hippocampal neurons by l-phenylalanine at concentrations observed during phenylketonuria. Mol. Psychiatry. 7 (2002) 359-367
46. Glushakov A.V., Dennis D.M., Sumners C., Seubert C.N., and Martynyuk A.E. L-phenylalanine selectively depresses currents at glutamatergic excitatory synapses. J. Neurosci. Res. 72 (2003) 116-124
47. Zagreda L., Goodman J., Druin D.P., McDonald D., and Diamond A. Cognitive deficits in a genetic mouse model of the most common biochemical cause of human mental retardation. J. Neurosci. 19 (1999) 6175-6182
48. Tang Y.P., Shimizu E., Dube G.R., Rampon C., Kerchner G.A., Zhuo M., Liu G., and Tsien J.Z. Genetic enhancement of learning and memory in mice. Nature 401 (1999) 63-69
49. Sarkissian C.N., Boulais D.M., McDonald J.D., and Scriver C.R. A hetreoallelic mutant mouse model: a new orthologue for human hyperphenylalaninemia. Mol. Genet. Metab. 69 (2002) 188-194
50. Mihalick S.M., Langlois J.C., Krienke J.D., and Dube W.V. An olfactory discrimination procedure for mice. J. Exp. Anal. Behav. 73 (2000) 305-318
51. Cabib S., Pascucci T., Ventura R., Romano V., and Puglisi-Allegra S. The behavioural profile of severe mental retardation in a genetic mouse model of phenylketonuria. Behav. Genet. 33 (2003) 301-310
52. Izquierdo I., Bevilaqua L.R., Rossato J.I., Bonini J.S., Da Silva W.C., Medina J.H., and Cammarota M. The connection between the hippocampal and the striatal memory systems of the brain: a review of recent findings. Neurotox. Res. 10 (2006) 113-121
53. enu2 mouse model for phenylketonuria. Pediatr. Res. 58 (2005) 283-287
54. Dyer C.A., Kendler A., Jean-Guillaume D., Awatramani R., Lee A., Mason L.M., and Kamholz J. GFAP-positive and myelin marker-positive glia in normal and pathologic environments. J. Neurosci. Res. 60 (2000) 412-426
55. Shefer S., Tint G.S., Jean-Guillaume D., Daikhin E., Kendler A., Nguyen L.B., Yudkoff M., and Dyer C.A. Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and forebrain pathology in the PKU mouse?. J. Neurosci. Res. 61 (2000) 549-563
56. Martynyuk A.E., Glushakov A.V., Sumners C., Laipis P.J., Dennis D.M., and Seubert C.N. Impaired glutamatergic transmission in the PKU brain. Mol. Genet. Metab. 86 (2005) S34-S42
57. Hörster F., Schwab M.A., Sauer S.W., Pietz J., Hoffmann G.F., Okun J.G., Kölker S., and Kins S. Phenylalanine reduces synaptic density in mixed cortical cultures from mice. Pediatr. Res. 59 (2006) 544-548
58. Nelson L., Johnson J.K., Freedman M., Lott I., Groot J., Chang M., Milgram N.W., and Head E. Learning and memory as a function of age in Down syndrome: a study using animal-based tasks. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 443-453
59. Havekes R., Nijholt I.M., Luiten P.G.M., and Van der Zee E.A. Differential involvement of hippocampal calcineurin during learning and reversal learning in a Y-maze task. Learn. Mem. 13 (2006) 753-759
60. Havekes R., Timmer M., and Van der Zee E.A. Regional differences in hippocampal PKA immunoreactivity after training and reversal training in a spatial Y-maze task. Hippocampus. 17 (2007) 338-348
61. Didden R., Sigafoos S., Green V.A., Korzilius H., Mouws C., Lancioni G.E., O'Reilly M.F., and Curfs L.M. Behavioural flexibility in individuals with Angelman syndrome, Down syndrome, non-specific intellectual disability and Autism spectrum disorder. J. Intellect. Disabil. Res. 52 (2008) 503-509
62. Heal L.W., Ross L.E., and Sanders B. Reversal and partial reversal in mental defectives and normal children of a comparable mental age. Am. J. Ment. Defic. 71 (1966) 411-416